Sarepta grants CEO Ingram $12M equity awards after 8-year gap

Sarepta Therapeutics, Inc.

CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.
Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.
First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.
Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.
Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.